Looking for the next Amazon or Tesla to invest at the Start?

2024年12月5日

CRISPR Therapeutics - revenue projection = Massive

I am accumulating shares. you may want to start looking into CrSp.Let's calculate the revenue potential for CRISPR Therapeutics based on their approved therapy and pipeline:

THERAPY 1: BEING ROLLED OUT AND APPROVED IN THE USA AND EUROPE

Casgevy (approved for sickle cell disease and beta-thalassemia):

Price per therapy: $2.2 million

Potential patient pool: 70 million

Assuming 2% adoption: 1.4 million patients

Potential revenue: $3.08 trillion

THERAPY 2:

CTX310 (Phase 1 for cardiovascular disease):

Assuming similar pricing and 1% adoption of global cardiovascular patients (520 million)Potential revenue: $1.144 trillion

THERAPY 3:

CTX320 (Phase 1 for elevated Lp(a)):20% of global population has elevated Lp(a), assuming 0.5% adoption

Potential revenue: $1.716 trillion

THERAPY 4:

CTX340 and CTX450 (preclinical):

Assuming more modest adoption due to earlier stage, estimate $500 billion each.Combined potential revenue: $1 trillion

Total potential revenue: $6.94 trillion

ASSUMPTION OF REVENUE POTENTIAL DISCOUNTED TO NET PRESENT VALUE AND THEN CALCULATION OF SHARE PRICE ASSUMPTION GIVEN THIS DATA:

Assuming this revenue is spread over 10 years and using a conservative 10% discount rate for NPV calculation:NPV = $6.94 trillion / (1.1^5) ≈ $4.31 trillion

CRISPR Therapeutics has approximately 79 million shares outstanding.Value per share: $4.31 trillion / 79 million ≈ $54,557

Projected share price (multiplied by 25, 25 is the mlptiple at which companies trade on average): $1,363,925

This calculation suggests an extremely high potential value. Competition, many copy cats and swindlers purporting the expertise, as usual with Biotech, you remember INO Inovio and that Korean Doctor, a fraud in my opinion (the stock wen from $33 to almost zero). Well CRSP is lead by two Nobel Prize winners, Harvard is in the mix and the Swiss are financing it, and they have already 44 Therapy Centers, and licensing the technology very quickly. This company is the real deal. Careful investing in the rest of the space, Pfizer already flopped, imagine Pfizer, that should tell you that this BioTech Space is only for salient technologies.

When people go back to see how they would have done with Amazon or Netflix, well here you have another technology company that can very well outdo them all.

Short Interest: 19.39 million shares

Float: Approximately 83.94 million shares (calculated from 23.10% of float shorted)

Cash: $2.0 billion as of June 2024

Growth Rate: Revenue growth of 19% over the past year

Debt: Zero debt reported

Volume: Average trading volume of 1.48 million shares per day

Days to Cover: 14.8 days

Additional information:

Short Interest Ratio: 13.31 Days to Cover

Short Interest % of Float: 23.10%

Cash Burn: $129 million in the last year

Cash Runway: Several years based on current burn rate

Market Capitalization: Approximately $4.2-$4.3 billion

The P/E ratio is not provided in the search results, which is common for biotechnology companies that may not yet have consistent earnings.

THE PERFECT CANDIDATE FOR A MASSIVE SHORT SQUEEZE.


#investments, #CRSP, #Crispr, #Therapy, #Therapeutics, #Get, #Rich, #Biotech, #Technology, #Medicine, #SickelCell
link to article: "linkedin.com/pulse/looking-next-amazon-tesla-invest-very-beginning-well-read-s-sc-n--0r8be/?trackingId=o+1DocTdTi+O+wk/qKV1yA=="

1月16日

註釋

CRSP Crispr Therapeutics .... $768 per share at present.... that is a 20x today
S. SC. N.
S. SC. N.
Exec.


January 15, 2025
CRISPR Therapeutics (CRSP) Overview:

Strategic Priorities: CRISPR is advancing its flagship product, CASGEVY, with strong demand and payer support, alongside expanding its pipeline with key updates expected in 2025.
Financial Health: Starting 2025 with a robust $1.9 billion in cash reserves, positioning the company for aggressive growth.

DCF Valuation Insights:

Future Value Projection: A highly optimistic scenario suggests a share price could reach around $1,078 in 5 years, based on aggressive market penetration, successful new therapies, and favorable market conditions.
Present Value Calculation: Discounting this future value back to the present using a 7% discount rate gives an intrinsic share value of approximately $768.73 today. This suggests significant potential upside if all goes perfectly.

2025 Milestones:

CASGEVY: Continued momentum with quarterly updates on patient access and treatment outcomes.
Pipeline Updates: Clinical advancements for CTX112, CTX310, CTX320, and CTX131 expected throughout 2025, potentially catalyzing stock movement.

Market Implications:

Earnings Imminent: CRISPR's next earnings are slated for February 18 or 19, 2025. Watch for updates on CASGEVY's commercial performance and any surprises in R&D progress which could sway investor sentiment.
Growth Potential: With a DCF suggesting a share price in the 900s in five years, and a present value near $768, the stock could be seen as undervalued, potentially driving interest if positive developments align with projections.

Investment Considerations:

High Risk/High Reward: The biotech sector's volatility, coupled with clinical trial outcomes and regulatory hurdles, means this valuation carries substantial risk.
Catalyst Events: Upcoming data updates and potential regulatory milestones in 2025 could serve as significant catalysts for share price movement.
Market Sentiment: If investors buy into the growth narrative supported by successful product launches and regulatory wins, CRSP might see accelerated appreciation towards these ambitious projections.

Conclusion: CRISPR Therapeutics stands at the forefront of gene editing with a promising pipeline and a strong balance sheet. The DCF model suggests exceptional growth potential, but investors should be mindful of the speculative nature of these projections in the dynamic biotech landscape. Earnings in mid-February could provide clarity on the company's trajectory, potentially moving the market based on the outcomes presented.